About this FactMed analysis covering adverse side effect reports of GEMZAR patients who developed ACANTHOLYSIS.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 1 individuals taking GEMZAR reported ACANTHOLYSIS to the FDA. A total of 9639 GEMZAR drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between GEMZAR and ACANTHOLYSIS. In doing so, we compare GEMZAR with other drugs that cause ACANTHOLYSIS, to help you evaluate whether or not GEMZAR causes ACANTHOLYSIS. Likewise, this page shows the most highly-reported side effects of GEMZAR, so you can see if ACANTHOLYSIS ranks among GEMZAR's most well-known side effects.
Summary Statistics
Reports of GEMZAR causing ACANTHOLYSIS: 1
Reports of any side effect of GEMZAR : 9639
Percentage of GEMZAR patients where ACANTHOLYSIS is a reported side effect: 0.0104%

FDA reports of any drug causing ACANTHOLYSIS : 33
Average percentage for all medicated patients where ACANTHOLYSIS is reported as a complication: 0.0002%

Physician opinion on GEMZAR as adverse event culprit:

Overall opinion for all reports of this drug:
Most frequent diagnoses/indications for prescribing GEMZAR:
PANCREATIC CARCINOMA ( 1387 patients )
NON-SMALL CELL LUNG CANCER ( 877 patients )
BREAST CANCER METASTATIC ( 309 patients )
LUNG NEOPLASM MALIGNANT ( 283 patients )
PANCREATIC CARCINOMA STAGE IV ( 251 patients )
OVARIAN CANCER ( 243 patients )
BILE DUCT CANCER ( 233 patients )
BREAST CANCER ( 222 patients )
BLADDER CANCER ( 190 patients )
PANCREATIC CARCINOMA METASTATIC ( 171 patients )
ADENOCARCINOMA PANCREAS ( 120 patients )
LUNG ADENOCARCINOMA ( 108 patients )
NEOPLASM MALIGNANT ( 101 patients )
PANCREATIC CARCINOMA NON-RESECTABLE ( 71 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 67 patients )
GALLBLADDER CANCER ( 64 patients )
CHEMOTHERAPY ( 57 patients )
TRANSITIONAL CELL CARCINOMA ( 56 patients )
DRUG USE FOR UNKNOWN INDICATION ( 55 patients )
LUNG CANCER METASTATIC ( 54 patients )
OVARIAN CANCER RECURRENT ( 53 patients )
HODGKIN'S DISEASE ( 48 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 47 patients )
ADENOCARCINOMA ( 45 patients )
NON-HODGKIN'S LYMPHOMA ( 44 patients )
NON-SMALL CELL LUNG CANCER RECURRENT ( 35 patients )
BRONCHIAL CARCINOMA ( 35 patients )
LUNG ADENOCARCINOMA STAGE IV ( 34 patients )
NON-SMALL CELL LUNG CANCER METASTATIC ( 32 patients )
LYMPHOMA ( 31 patients )
PANCREATIC CARCINOMA RECURRENT ( 28 patients )
NON-SMALL CELL LUNG CANCER STAGE IIIB ( 27 patients )
PANCREATIC CARCINOMA STAGE III ( 27 patients )
PLEURAL MESOTHELIOMA MALIGNANT ( 26 patients )
GALLBLADDER CANCER STAGE IV ( 26 patients )
SQUAMOUS CELL CARCINOMA ( 24 patients )
LUNG ADENOCARCINOMA STAGE III ( 24 patients )
SARCOMA ( 24 patients )
METASTASES TO LIVER ( 23 patients )
HEPATIC NEOPLASM MALIGNANT ( 23 patients )
LUNG CARCINOMA CELL TYPE UNSPECIFIED STAGE IV ( 22 patients )
OVARIAN CANCER METASTATIC ( 22 patients )
BREAST CANCER STAGE IV ( 22 patients )
BILE DUCT CANCER STAGE IV ( 22 patients )
LUNG SQUAMOUS CELL CARCINOMA STAGE UNSPECIFIED ( 21 patients )
METASTATIC NEOPLASM ( 21 patients )
BILE DUCT CANCER RECURRENT ( 20 patients )
OVARIAN EPITHELIAL CANCER ( 20 patients )
MESOTHELIOMA ( 19 patients )
METASTATIC CARCINOMA OF THE BLADDER ( 19 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 19 patients )
GERM CELL CANCER ( 18 patients )
METASTATIC RENAL CELL CARCINOMA ( 17 patients )
PANCREATIC CARCINOMA STAGE II ( 16 patients )
CARCINOMA ( 16 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 16 patients )
BLADDER TRANSITIONAL CELL CARCINOMA ( 16 patients )
NEOPLASM ( 16 patients )
BLADDER CANCER STAGE IV ( 15 patients )
MYCOSIS FUNGOIDES ( 15 patients )
PLEURAL MESOTHELIOMA ( 14 patients )
BILE DUCT CANCER STAGE III ( 14 patients )
METASTASES TO LUNG ( 14 patients )
METASTASES TO BONE ( 14 patients )
LUNG SQUAMOUS CELL CARCINOMA STAGE IV ( 13 patients )
SMALL INTESTINE CARCINOMA ( 12 patients )
LUNG ADENOCARCINOMA METASTATIC ( 12 patients )
CERVIX CARCINOMA ( 12 patients )
BILE DUCT CANCER NON-RESECTABLE ( 12 patients )
URETERIC CANCER ( 11 patients )
COLON CANCER ( 10 patients )
METASTASIS ( 10 patients )
GALLBLADDER CANCER NON-RESECTABLE ( 10 patients )
PROSTATE CANCER ( 10 patients )
LUNG CARCINOMA CELL TYPE UNSPECIFIED STAGE III ( 10 patients )
BREAST CANCER RECURRENT ( 10 patients )
RENAL CELL CARCINOMA STAGE UNSPECIFIED ( 9 patients )
BILIARY CANCER METASTATIC ( 9 patients )
LEIOMYOSARCOMA METASTATIC ( 9 patients )
MESOTHELIOMA MALIGNANT ( 9 patients )
THYMOMA MALIGNANT ( 9 patients )
LUNG SQUAMOUS CELL CARCINOMA RECURRENT ( 8 patients )
BONE SARCOMA ( 8 patients )
LUNG ADENOCARCINOMA RECURRENT ( 8 patients )
RENAL CELL CARCINOMA ( 8 patients )
MALIGNANT NEOPLASM OF AMPULLA OF VATER ( 8 patients )
PERITONEAL CARCINOMA ( 8 patients )
LEIOMYOSARCOMA ( 8 patients )
PROPHYLAXIS ( 7 patients )
HEAD AND NECK CANCER ( 7 patients )
ACUTE MYELOID LEUKAEMIA ( 7 patients )
URETHRAL CANCER ( 7 patients )
BILE DUCT CANCER STAGE II ( 7 patients )
LARGE CELL LUNG CANCER STAGE IV ( 7 patients )
LUNG NEOPLASM ( 7 patients )
RENAL CANCER ( 6 patients )
GALLBLADDER CANCER RECURRENT ( 6 patients )
GASTRIC CANCER ( 6 patients )
PANCREATIC NEOPLASM ( 6 patients )
SARCOMA UTERUS ( 6 patients )
NON-SMALL CELL LUNG CANCER STAGE III ( 6 patients )
LUNG SQUAMOUS CELL CARCINOMA STAGE III ( 5 patients )
HODGKIN'S DISEASE REFRACTORY ( 5 patients )
LUNG CARCINOMA CELL TYPE UNSPECIFIED STAGE 0 ( 5 patients )
HEPATIC NEOPLASM ( 5 patients )
PANCREATIC CARCINOMA STAGE I ( 5 patients )
LUNG CARCINOMA CELL TYPE UNSPECIFIED RECURRENT ( 5 patients )
ENDOMETRIAL CANCER ( 5 patients )
UTERINE CANCER ( 5 patients )
BREAST CANCER STAGE III ( 4 patients )
PANCREATIC CARCINOMA RESECTABLE ( 4 patients )
ACUTE LYMPHOCYTIC LEUKAEMIA ( 4 patients )
T-CELL LYMPHOMA ( 4 patients )
URETHRAL CANCER METASTATIC ( 4 patients )
UTERINE LEIOMYOSARCOMA ( 4 patients )
BLADDER ADENOCARCINOMA STAGE UNSPECIFIED ( 4 patients )
PERITONEAL MESOTHELIOMA MALIGNANT ( 4 patients )
MALIGNANT URINARY TRACT NEOPLASM ( 4 patients )
NEOPLASM RECURRENCE ( 4 patients )
BLADDER CANCER RECURRENT ( 4 patients )
TRANSITIONAL CELL CANCER OF THE RENAL PELVIS AND URETER ( 4 patients )
CONSTIPATION ( 4 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 4 patients )
MALIGNANT HEPATOBILIARY NEOPLASM ( 4 patients )
OVARIAN NEOPLASM ( 4 patients )
METASTASES TO LYMPH NODES ( 4 patients )
MALIGNANT PERITONEAL NEOPLASM ( 4 patients )
MANTLE CELL LYMPHOMA ( 4 patients )
COLON CANCER METASTATIC ( 3 patients )
BLADDER NEOPLASM ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
OVARIAN EPITHELIAL CANCER RECURRENT ( 3 patients )
PLEURAL NEOPLASM ( 3 patients )
METASTASES TO CENTRAL NERVOUS SYSTEM ( 3 patients )
BILE DUCT CANCER STAGE I ( 3 patients )
DISEASE PROGRESSION ( 3 patients )
INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE II ( 3 patients )
NASOPHARYNGEAL CANCER ( 3 patients )
TESTICULAR MASS ( 3 patients )
ENDOMETRIAL CANCER RECURRENT ( 3 patients )
MALIGNANT NEOPLASM PROGRESSION ( 3 patients )
METASTASES TO PLEURA ( 3 patients )
ALVEOLAR SOFT PART SARCOMA ( 3 patients )
FALLOPIAN TUBE CANCER ( 3 patients )
YOLK SAC TUMOUR SITE UNSPECIFIED ( 3 patients )
COLON CANCER RECURRENT ( 3 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 3 patients )
OVARIAN EPITHELIAL CANCER STAGE III ( 3 patients )
BURKITT'S LYMPHOMA ( 3 patients )
LUNG ADENOCARCINOMA STAGE II ( 3 patients )
CARCINOMA IN SITU ( 3 patients )
GASTRIC CANCER RECURRENT ( 3 patients )
RETROPERITONEAL NEOPLASM ( 3 patients )
TESTICULAR CHORIOCARCINOMA STAGE III ( 3 patients )
CERVIX CARCINOMA STAGE I ( 3 patients )
SARCOMA METASTATIC ( 3 patients )
TESTIS CANCER ( 3 patients )
ADRENOCORTICAL CARCINOMA ( 3 patients )
CHORIOCARCINOMA ( 3 patients )
OESOPHAGEAL CARCINOMA ( 3 patients )
METASTATIC BRONCHIAL CARCINOMA ( 2 patients )
PHARYNGEAL CANCER STAGE UNSPECIFIED ( 2 patients )
FIBROSARCOMA ( 2 patients )
LIPOSARCOMA ( 2 patients )
COLORECTAL CANCER ( 2 patients )
METASTATIC GASTRIC CANCER ( 2 patients )
BREAST NEOPLASM ( 2 patients )
MESOTHELIOMA MALIGNANT RECURRENT ( 2 patients )
BLADDER SQUAMOUS CELL CARCINOMA STAGE UNSPECIFIED ( 2 patients )
SYNOVIAL SARCOMA ( 2 patients )
MALIGNANT LYMPHOID NEOPLASM ( 2 patients )
MYCOSIS FUNGOIDES RECURRENT ( 2 patients )
ADENOID CYSTIC CARCINOMA ( 2 patients )
PROSTATE CANCER METASTATIC ( 2 patients )
METASTASES TO OVARY ( 2 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 2 patients )
BREAST CANCER STAGE I ( 2 patients )
LEUKAEMIA RECURRENT ( 2 patients )
HETEROPLASIA ( 2 patients )
SMALL INTESTINE LEIOMYOSARCOMA ( 2 patients )
RENAL CANCER METASTATIC ( 2 patients )
HODGKIN'S DISEASE RECURRENT ( 2 patients )
PREMEDICATION ( 2 patients )
BONE NEOPLASM ( 2 patients )
NON-SMALL CELL LUNG CANCER STAGE I ( 2 patients )
PANCREATIC NEUROENDOCRINE TUMOUR ( 2 patients )
LARGE CELL CARCINOMA OF THE RESPIRATORY TRACT STAGE UNSPECIFIED ( 2 patients )
PARAGANGLION NEOPLASM MALIGNANT ( 2 patients )
PALLIATIVE CARE ( 2 patients )
BILIARY NEOPLASM ( 2 patients )
HEPATIC CANCER STAGE IV ( 2 patients )
SEMINOMA ( 2 patients )
EWING'S SARCOMA ( 2 patients )
VULVAL CANCER ( 1 patients )
BLADDER CANCER STAGE III ( 1 patients )
HEPATOSPLENIC T-CELL LYMPHOMA ( 1 patients )
TRANSITIONAL CELL CANCER OF THE RENAL PELVIS AND URETER RECURRENT ( 1 patients )
B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
SOFT TISSUE DISORDER ( 1 patients )
TRANSITIONAL CELL CARCINOMA METASTATIC ( 1 patients )
NON-HODGKIN'S LYMPHOMA RECURRENT ( 1 patients )
RENAL CANCER STAGE IV ( 1 patients )
CONNECTIVE TISSUE NEOPLASM ( 1 patients )
HODGKIN'S DISEASE NODULAR SCLEROSIS STAGE UNSPECIFIED ( 1 patients )
TUMOUR MARKER INCREASED ( 1 patients )
BRONCHIOLOALVEOLAR CARCINOMA ( 1 patients )
LUNG ADENOCARCINOMA STAGE I ( 1 patients )
BONE CANCER METASTATIC ( 1 patients )
Drugs with high FDA adverse event association with ACANTHOLYSIS:

AMBIEN (10 patients)
ABRAXANE (9 patients)
ACIPHEX (9 patients)
AMPICILLIN (9 patients)
ASPIRIN (9 patients)
ATIVAN (9 patients)
AVASTIN (9 patients)
CYMBALTA (9 patients)
LEVOTHYROXINE SODIUM (9 patients)
NORCO (9 patients)
RADIATION (9 patients)
VICODIN (9 patients)
XELODA (9 patients)
ZOLOFT (9 patients)
ZOMETA (9 patients)
ZOFRAN (8 patients)
ARANESP (7 patients)
CAPECITABINE (7 patients)
CEFTRIAXONE (7 patients)
CEPHALEXIN (7 patients)
CIPROFLOXACIN (7 patients)
COLACE (7 patients)
DILAUDID (7 patients)
DOXIL (7 patients)
FEMARA (7 patients)
HYDROCODONE BITARTRATE AND ACETAMINOPHEN (7 patients)
KEFLEX (7 patients)
LASIX (7 patients)
LORAZEPAM (7 patients)
NAPROSYN (7 patients)
NEULASTA (7 patients)
NIACIN (7 patients)
PERCOCET (7 patients)
PROVIGIL (7 patients)
RITALIN (7 patients)
SYNTHROID (7 patients)
TAXOTERE (7 patients)
VANCOMYCIN (7 patients)
VANCOMYCIN HCL (7 patients)
DEXAMETHASONE (6 patients)
FENTANYL (6 patients)
CYCLOSPORINE (4 patients)
PLAVIX (4 patients)
RELAFEN (4 patients)
ACETYLSALICYLIC ACID SRT (3 patients)
ACYCLOVIR (3 patients)
AMITIZA (3 patients)
NABUMETONE (3 patients)
NEXIUM (3 patients)
NIFEDIPINE (3 patients)
XIFAXAN (3 patients)
ALDACTAZIDE (2 patients)
AMLOR (2 patients)
AZATHIOPRINE (2 patients)
CLINDAMYCIN (2 patients)
COZAAR (2 patients)
DEPAKENE (2 patients)
DEPAS (2 patients)
DIGOXIN (2 patients)
DIPYRIDAMOL (2 patients)
EMPYNASE (2 patients)
ENALAPRIL MALEATE (2 patients)
ETRETINATE (2 patients)
FRACTAL (2 patients)
FUCIDIN CREAM (2 patients)
FUROSEMIDE (2 patients)
GAMUNEX (2 patients)
GLUCOR (2 patients)
HALCION (2 patients)
ISOSORBIDE MONONITRATE (2 patients)
LAMICTAL (2 patients)
LAXOBERON (2 patients)
LEVEMIR (2 patients)
MAGLAX (2 patients)
METHYLPREDNISOLONE (2 patients)
MINOCYCLIN (2 patients)
MOPRAL (2 patients)
MORPHINE (2 patients)
NITROGLYCERIN (2 patients)
PREDNISOLONE (2 patients)
PREDNISONE (2 patients)
SECTRAL (2 patients)
STILNOX (2 patients)
THEOPHYLLINE (2 patients)
TOPICAL ANTISEPTICS (2 patients)
ACENOCOUMAROL (1 patients)
ACENOCOUMAROL (ACENOCOUMAROL) (1 patients)
ACTIFED (1 patients)
AMILORIDE (1 patients)
AMILORIDE (AMILORIDE HYDROCHLORIDE) (1 patients)
ARNESP (1 patients)
ATENOLOL (1 patients)
ATORVASTATIN CALCIUM (1 patients)
BEMYLID (1 patients)
BETAMETHASONE DIPROPIIONATE (1 patients)
BETAMETHASONE DIPROPIONATE (1 patients)
CARBAMAZEPINE (1 patients)
CEFIXIME (1 patients)
CILAZAPRIL (1 patients)
CIPROFLOXACIN HCL (1 patients)
CIPROFLOXACIN IV (1 patients)
CISPLATIN (1 patients)
COPEGUS (1 patients)
DEXAMETHASONE ACETATE (1 patients)
DOXIUM (CALCIUM DOBESILATE) (1 patients)
ETHYOL (1 patients)
ETOPOSIDE (1 patients)
FENTANYL-100 (1 patients)
FILGRASTIM (FILGRASTIM) (1 patients)
FINASTERIDE (1 patients)
GEMZAR (1 patients)
GLIBENCLAMIDE (1 patients)
GLIMEPIRIDE (1 patients)
HEMERAN GEL (HEPARINOID) (1 patients)
HUMAN INSULIN (1 patients)
INSULIN ACTRAPID HUMAN (1 patients)
INTRON A (1 patients)
IRINOTECAN HCL (1 patients)
L-THYROXIN (1 patients)
LACIDIPINE (1 patients)
LACIDIPINE (LACIDIPINE) (1 patients)
MAGNESIUM OXIDE (MAGNESIUM OXIDE) (1 patients)
METHOTREXATE (1 patients)
MS CONTIN (1 patients)
OXYCODONE HCL (1 patients)
PEG-INTRON (1 patients)
PHENYTOIN (1 patients)
PRAVASTATIN (1 patients)
PRAVASTATIN SODIUM (1 patients)
PREDNISONE TAB (1 patients)
RADIATION THERAPY (1 patients)
REBETOL (1 patients)
RIBAVIRIN (1 patients)
TAREG (1 patients)
TOPICAL MEDICATIONS (FOR PSORIASIS) (1 patients)
ZETIA (1 patients)
Most common side effects for patients taking GEMZAR:
MALIGNANT NEOPLASM PROGRESSION (884 patients)
ANAEMIA (815 patients)
DYSPNOEA (785 patients)
PYREXIA (775 patients)
DEATH (637 patients)
NAUSEA (635 patients)
PLEURAL EFFUSION (589 patients)
PAIN (571 patients)
INTERSTITIAL LUNG DISEASE (565 patients)
THROMBOCYTOPENIA (554 patients)
PLATELET COUNT DECREASED (502 patients)
WHITE BLOOD CELL COUNT DECREASED (494 patients)
OEDEMA PERIPHERAL (457 patients)
VOMITING (457 patients)
FATIGUE (446 patients)
PNEUMONIA (406 patients)
ASTHENIA (396 patients)
DIARRHOEA (386 patients)
BONE DISORDER (369 patients)
ANXIETY (358 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (350 patients)
BACK PAIN (344 patients)
OSTEONECROSIS OF JAW (339 patients)
DEHYDRATION (333 patients)
HAEMOGLOBIN DECREASED (330 patients)
TOOTH EXTRACTION (312 patients)
RASH (302 patients)
OSTEONECROSIS (300 patients)
CONSTIPATION (296 patients)
METASTASES TO BONE (291 patients)
PANCYTOPENIA (288 patients)
NEUTROPENIA (287 patients)
HEADACHE (281 patients)
IMPAIRED HEALING (280 patients)
PAIN IN EXTREMITY (280 patients)
DECREASED APPETITE (276 patients)
NEOPLASM PROGRESSION (275 patients)
METASTASES TO LIVER (271 patients)
OSTEOMYELITIS (266 patients)
ABDOMINAL PAIN (264 patients)
DEEP VEIN THROMBOSIS (263 patients)
RENAL FAILURE (259 patients)
ASCITES (255 patients)
PULMONARY EMBOLISM (250 patients)
ARTHRALGIA (248 patients)
SEPSIS (243 patients)
WEIGHT DECREASED (239 patients)
COUGH (234 patients)
ERYTHEMA (234 patients)
RESPIRATORY FAILURE (232 patients)
HYPERTENSION (231 patients)
MALAISE (228 patients)
CONFUSIONAL STATE (226 patients)
RENAL FAILURE ACUTE (223 patients)
CHEST PAIN (216 patients)
DISEASE PROGRESSION (214 patients)
HYPOAESTHESIA (213 patients)
DIZZINESS (212 patients)
NEUROPATHY PERIPHERAL (212 patients)
HAEMOLYTIC URAEMIC SYNDROME (211 patients)
CELLULITIS (210 patients)
PNEUMONITIS (210 patients)
OSTEOARTHRITIS (209 patients)
NEOPLASM MALIGNANT (208 patients)
PAIN IN JAW (204 patients)
SWELLING (195 patients)
FALL (195 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (192 patients)
METASTASES TO LUNG (189 patients)
TOOTHACHE (189 patients)
INFECTION (188 patients)
BLOOD CREATININE INCREASED (186 patients)
NEUTROPHIL COUNT DECREASED (184 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (184 patients)
URINARY TRACT INFECTION (183 patients)
LUNG DISORDER (177 patients)
ALANINE AMINOTRANSFERASE INCREASED (175 patients)
ATELECTASIS (174 patients)
BONE MARROW FAILURE (171 patients)
LEUKOPENIA (167 patients)
CHILLS (165 patients)
INSOMNIA (163 patients)
DEPRESSION (162 patients)
BONE PAIN (161 patients)
PARAESTHESIA (160 patients)
CEREBRAL INFARCTION (158 patients)
CHOLANGITIS (158 patients)
INJURY (158 patients)
ANOREXIA (155 patients)
HYPOTENSION (148 patients)
SPINAL OSTEOARTHRITIS (146 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (146 patients)
CARDIAC FAILURE (146 patients)
LYMPHADENOPATHY (145 patients)
FEBRILE NEUTROPENIA (144 patients)
CONDITION AGGRAVATED (144 patients)
TACHYCARDIA (144 patients)
ANHEDONIA (141 patients)
PRURITUS (137 patients)
PULMONARY OEDEMA (136 patients)
INTERVERTEBRAL DISC DEGENERATION (136 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (135 patients)
PERICARDIAL EFFUSION (134 patients)
HEPATIC FAILURE (134 patients)
HYPOKALAEMIA (130 patients)
CONVULSION (130 patients)
STOMATITIS (129 patients)
MYOCARDIAL INFARCTION (129 patients)
LOOSE TOOTH (129 patients)
TOOTH DISORDER (127 patients)
C-REACTIVE PROTEIN INCREASED (127 patients)
ALOPECIA (126 patients)
OEDEMA (124 patients)
MUCOSAL INFLAMMATION (123 patients)
OFF LABEL USE (122 patients)
WHITE BLOOD CELL COUNT INCREASED (122 patients)
HYPOXIA (122 patients)
GENERALISED OEDEMA (121 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (121 patients)
MUSCULAR WEAKNESS (120 patients)
JAUNDICE (119 patients)
INTERVERTEBRAL DISC PROTRUSION (117 patients)
PRIMARY SEQUESTRUM (117 patients)
SINUSITIS (116 patients)
DECREASED INTEREST (116 patients)
ORAL PAIN (116 patients)
BRONCHITIS (115 patients)
BONE DEBRIDEMENT (114 patients)
DENTAL CARIES (114 patients)
TOOTH LOSS (113 patients)
GASTROINTESTINAL HAEMORRHAGE (113 patients)
ACUTE RESPIRATORY DISTRESS SYNDROME (112 patients)
SYNCOPE (112 patients)
WEIGHT INCREASED (111 patients)
DYSPHAGIA (110 patients)
DRUG TOXICITY (109 patients)
TOOTH ABSCESS (109 patients)
EMOTIONAL DISTRESS (108 patients)
BONE LESION (107 patients)
RENAL IMPAIRMENT (106 patients)
EPISTAXIS (105 patients)
MASTICATION DISORDER (105 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (105 patients)
BLOOD UREA INCREASED (104 patients)
LUNG INFILTRATION (104 patients)
PULMONARY FIBROSIS (104 patients)
LUNG NEOPLASM (104 patients)
RECTAL HAEMORRHAGE (103 patients)
THROMBOSIS (102 patients)
ARTHRITIS (97 patients)
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (97 patients)
DEFORMITY (96 patients)
MUSCULOSKELETAL PAIN (94 patients)
THROMBOTIC MICROANGIOPATHY (94 patients)
CHEST DISCOMFORT (94 patients)
GINGIVAL PAIN (94 patients)
HAEMATOCRIT DECREASED (94 patients)
STAPHYLOCOCCAL INFECTION (94 patients)
PANCREATIC CARCINOMA (92 patients)
MENTAL STATUS CHANGES (91 patients)
PLATELET COUNT INCREASED (91 patients)
THROMBOTIC THROMBOCYTOPENIC PURPURA (91 patients)
SEPTIC SHOCK (90 patients)
RED BLOOD CELL COUNT DECREASED (90 patients)
MITRAL VALVE INCOMPETENCE (89 patients)
HAEMORRHOIDS (89 patients)
CONTUSION (89 patients)
DRUG INEFFECTIVE (89 patients)
PATHOLOGICAL FRACTURE (88 patients)
CHOLELITHIASIS (87 patients)
DYSPNOEA EXERTIONAL (86 patients)
OSTEOPOROSIS (86 patients)
DIVERTICULUM (86 patients)
METASTASES TO SPINE (86 patients)
BLOOD PRESSURE DECREASED (85 patients)
MUSCLE SPASMS (85 patients)
RENAL CYST (85 patients)
TREMOR (85 patients)
NECK PAIN (84 patients)
LIVER DISORDER (84 patients)
PURULENT DISCHARGE (84 patients)
BREAST CANCER METASTATIC (83 patients)
GINGIVAL INFECTION (83 patients)
BLOOD BILIRUBIN INCREASED (82 patients)
HIATUS HERNIA (82 patients)
INFLAMMATION (81 patients)
DISABILITY (81 patients)
MULTI-ORGAN FAILURE (80 patients)
METASTASES TO LYMPH NODES (80 patients)
PULMONARY TOXICITY (79 patients)
LOSS OF CONSCIOUSNESS (79 patients)
OESOPHAGITIS (79 patients)
GINGIVAL DISORDER (78 patients)
CARDIOMEGALY (77 patients)
HYPONATRAEMIA (76 patients)
CARDIOMYOPATHY (76 patients)
HEPATIC STEATOSIS (76 patients)
OSTEOLYSIS (75 patients)
HAEMATURIA (75 patients)
OSTEOPENIA (74 patients)
CARDIAC FAILURE CONGESTIVE (74 patients)
EXCESSIVE GRANULATION TISSUE (74 patients)
GAIT DISTURBANCE (74 patients)
URTICARIA (74 patients)
HYDRONEPHROSIS (73 patients)
FISTULA (73 patients)
MYALGIA (73 patients)
SWELLING FACE (73 patients)
HYPERHIDROSIS (72 patients)
BLOOD GLUCOSE INCREASED (72 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.


Recent FactMed Activity for GEMZAR


Issue Description / Topic Timestamp
QUESTION
ASCITES
My sister-in-law is taking Gemzar for pancreatic cancer. She now has ascites. She had a paracentesis in ZMarch (6600 ml), one on 5/26 (8500 ml) and now has a PleurX cath which is to be drained every day. She had 2ooml drained today per home health but is leaking constantly around the catheter. Her Dr informed her that her insurance will not pay for chemo unless Gemzar is included in the regimen. What can be done to get this to change? She can't move without leaking copious amounts of fluid around the cath. Deb 2016-06-01 16:23:29
QUESTION
ERECTILE DYSFUNCTION
Any known problems with taking Viagra while getting Gemzar chemo? Thanks 2017-07-04 15:32:34
QUESTION
ERECTILE DYSFUNCTION
Any known problems with taking Viagra while getting Gemzar chemo? Thanks 2017-07-04 16:12:06

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about ACANTHOLYSIS and GEMZAR, post it here. You may receive a response from a fellow patient - or a leading expert in the field.
Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking GEMZAR, post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.
Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in GEMZAR. This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.
We are currently accepting registration for GEMZAR experts. If you are a healthcare provider experienced in prescribing GEMZAR, please register here.
giCould not connect: